Our Partners

ElevateBio removes barriers to accelerate the development of visionary therapies

Viralym-M (ALVR105)
Multi-VSTs targeting BK Virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), Epstein-Barr (EBV), and Human Herpesvirus-6 (HHV-6)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of Virus-Associated Hemorrhagic-Cystitis
Treatment of CMV
Treatment of ADV
Prevention of BKV, CMV, AdV, EBV, HHV-6 and JCV
BKV Pre-emptive Treatment in KT
Treatment of CMV
ALVR106
Multi-VSTs targeting Respiratory syncytial virus (RSV), Influenza, Parainfluenza Virus (PIV), and Human Metapneumovirus (hMPV)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of RSV, Influenza, PIV, & hMPV
IND Cleared in Q4 2020
Treatment of RSV, Influenza, PIV, & hMPV
ALVR109
Single-VST targeting SARS-CoV-2
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of COVID-19
ALVR107
Single-VST targeting Hepatitis B (HBV)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of HBV
ALVR108
Single-VST targeting Human Herpesvirus-8 (HHV-8)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of HHV-8
HA-1 TCR
T cell receptor (TCR) T cell therapy targeting HA-1 expressing tumors designed to manage post-hematopoietic stem cell transplant leukemic relapse
Indication
Preclinical
Phase 1
Phase 2
Phase 3
HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Enabling
Our Partners

We’re the partner of choice for the world’s most innovative biopharma companies and academic institutions. Take a look at the projects we’re helping our partners achieve.

ElevateBio's breadth of expertise is delivering a wide set of advanced modalities for our partners

We leverage our platform technologies and ecosystem of manufacturing capabilities to drive innovation

Developing iPSC-Derived Allogeneic Immune Therapies

In collaboration with George Daley, M.D, Ph.D. and Boston Children’s Hospital, ElevateBio established a new company to develop off-the-shelf immune therapies derived from induced pluripotent stem cells (iPSCs). The company is founded upon a novel differentiation process that develops iPSCs into mature immune cells, which was detailed in a peer-reviewed publication in Cell Stem Cell. This NewCo is enabled by our iPSC and gene editing technologies and scale-up manufacturing capabilities to develop a broad pipeline of iPSC-derived therapies.

Learn More

Advancing the Discovery and Development of Regenerative Medicines with CIRM

ElevateBio partnered with the California Institute for Regenerative Medicine (CIRM) to develop iPSC-derived therapeutics. Through the collaboration, we are providing academic institutions and biopharmaceutical companies access to our integrated ecosystem of iPSC lines, vector technology, process development and manufacturing capabilities to accelerate the discovery and development of cell and gene therapies.

Learn More

Manufacturing Cell & Gene Therapies with Research Institutes

ElevateBio and Massachusetts General Hospital (MGH) formed a 10-year alliance agreement to provide MGH with preferred access to our BaseCamp process development and manufacturing facility in Waltham, Mass. for development and production of cell and gene therapies developed at MGH.

Learn More

Translating Research into Life-Changing Treatments

ElevateBio and Boston Children’s Hospital entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Children’s. The collaboration enables ElevateBio and Boston Children’s to form multiple cell and gene therapy companies together while providing researchers access to our enabling technologies, manufacturing capabilities and leading expertise.

Learn More

Partner With Us

Wherever you are in your cell and gene therapy (CGT) product life cycle, we come alongside you to strengthen and accelerate the development of life-transformative CGTs.

What Our Partners are Saying

Collaboration with ElevateBio [lets us] outsource all MFG, and [we] are able to leverage [their] cell bio expertise. Their strategy was capital efficient and saved time: 6 months after launch had baseline MFG process that took ~1 year off IND.

- Samantha Singer, Abata CEO

Work with a team that delivers decades of experience

Meet the scientists and operators that bring decades of shared knowledge to the development of life transforming cell and gene therapies. Their knowhow moves potential product candidates from concept to commercialization.

meet the team